08/29/2026
📣 Presented today at from JAMA, JAMA Cardiology, and JAMA Network Open:
➡️ From JAMA:
Among patients with acute treated with percutaneous coronary intervention, evolocumab before the procedure did not reduce all-cause death or unplanned cardiovascular hospitalization at 1 year vs standard care.
🔗 Read the study: https://ja.ma/3SC0YGY
💬 Read the editorial by Kausik Ray, MD, and Christophe A. T. Stevens, PhD: https://ja.ma/4xxZtZK
📊 Read the research summary: https://ja.ma/4xyHXES
For persistent , pulsed field ablation with posterior wall isolation plus pulmonary vein isolation did not significantly reduce atrial tachyarrhythmia recurrence vs pulmonary vein isolation alone.
🔗 Read the study: https://ja.ma/4ckD7m1
📊 Read the research summary: https://ja.ma/3UeZ3sF
Among adults with established or high cardiovascular risk and recent nonadherence, digital outreach improved 14-day statin refill vs usual communication.
🔗 Read the study: https://ja.ma/4qKQF05
💬 Read the editorial by Luke Laffin, MD: https://ja.ma/4i2sCYg
📊 Read the research summary: https://ja.ma/4gGiWA8
➡️ From JAMA Cardiology:
In patients with , a causal endotype-based classification identified distinct cardiac/coronary, cardiac/noncoronary, systemic, and indeterminate groups with different clinical profiles and 1-year outcomes.
🔗 Read the study: https://ja.ma/3SFFIQF
💬 Read the editorial by Gjin Ndrepepa, MD, and Adnan Kastrati, MD: https://ja.ma/3SzTgxg
➡️ From JAMA Network Open:
Among 412 947 elective ablation procedures in Japan, in-hospital mortality was 0.029% and remained low during a decade of rapid growth in procedural volume and the number of hospitals performing ablation.
🔗 Read the study: https://ja.ma/4A3lfq7
